KEANAISSANCE – The Mediterranean Summit of Tech Bio and Wellness
KEANAISSANCE, the Bi-Annual Festival on the Island of Kea, Greece announces its 2026 Spring Summit will be Showcasing the Leaders in Wellness, Tech Bio and Medtech at the KEANAISSANCE May 2026 Summit.
The Goal of the Summit is to Optimise the Capital, Awareness, Adoption and Connectivity across the Mediterranean for Entrepreneur-Led Innovation in this BlueZone, the Mediterranean which Ernst & Young has referred to as the 2ndLargest GDP Zone in the world after the US. (2014 Rome Summit E&Y)
KEANAISSANCE will host 150 Delegates for 5 Days on Kea which will include a Pre-Summit to meet leading Medical and Healthcare Professionals in Athens as well as to tour Kea and have 2 full dates of Summit with Keynotes and a Post-Summit of Wellness.
The Date for the Summit is May 11-15, 2026
May on Kea: It’s warm, beautiful, and sunny — daytime highs of 24–28°C (75–82°F), nights around 18–22°C (64–72°F), and sea temperatures of 20–22°C (68–72°F). Sunrise is about 05:45 AM, sunset about 08:30 PM (a 14h 45mday). Conditions are described as “Warm, increasing sunshine”, with rare light showers.
Global Wellness Summit: Comprehensive Wellness Ecosystem
11 Integrated Wellness Domains:
- Wellness Real Estate Research Focus: Intentional design of living and working environments Corporate Opportunities:
- Sustainable building technologies
- Health-integrated architectural design
- Smart wellness infrastructure
- Key Sponsors: Real estate developers, construction firms, urban planning companies
- Physical Activity Research Focus: Innovative approaches to movement and fitness Corporate Opportunities:
- Fitness technology development
- Active recreation platforms
- Performance optimization tools
- Key Sponsors: Sports tech companies, fitness equipment manufacturers, wearable tech firms
- Healthy Eating, Nutrition & Weight Loss Research Focus: Holistic nutritional approaches and metabolic health Corporate Opportunities:
- Functional food innovation
- Personalized nutrition platforms
- Metabolic health technologies
- Key Sponsors: Food and beverage companies, nutritional science firms, supplement manufacturers
- Mental Wellness Research Focus: Psychological and cognitive health strategies Corporate Opportunities:
- Neurotechnology development
- Mental health digital platforms
- Stress management innovations
- Key Sponsors: Mental health tech firms, digital wellness platforms, psychological research institutions
- Workplace Wellness Research Focus: Organizational health and employee well-being Corporate Opportunities:
- Employee wellness program design
- Corporate health optimization technologies
- Productivity and well-being integration
- Key Sponsors: HR technology firms, corporate wellness providers, management consulting companies
- Public Health, Prevention & Personalized Medicine Research Focus: Advanced preventative and individualized healthcare Corporate Opportunities:
- Genetic screening technologies
- Predictive health platforms
- Personalized medical interventions
- Key Sponsors: Healthcare technology companies, pharmaceutical firms, medical research institutions
- Traditional & Complementary Medicine Research Focus: Integrating ancient wisdom with modern healthcare Corporate Opportunities:
- Holistic health technology
- Alternative medicine research
- Cultural wellness innovation
- Key Sponsors: Integrative medicine providers, traditional healing institutions, research organizations
- Personal Care & Beauty Research Focus: Holistic approaches to personal care and appearance Corporate Opportunities:
- Advanced skincare technologies
- Personalized beauty solutions
- Wellness-integrated beauty platforms
- Key Sponsors: Cosmetic companies, beauty tech firms, personal care brands
- Wellness Tourism Research Focus: Regenerative and transformative travel experiences Corporate Opportunities:
- Wellness travel platform development
- Destination health experiences
- Transformative tourism technologies
- Key Sponsors: Hospitality companies, travel technology firms, tourism boards
- Spas Research Focus: Therapeutic and restorative practices Corporate Opportunities:
- Advanced spa technologies
- Holistic treatment innovations
- Wellness experience design
- Key Sponsors: Spa equipment manufacturers, wellness center operators, hospitality brands
- Thermal/Mineral Springs Research Focus: Therapeutic water-based wellness approaches Corporate Opportunities:
- Hydrotherapy technology
- Mineral wellness innovations
- Therapeutic water experience design
- Key Sponsors: Wellness resort developers, hydrotherapy equipment manufacturers, natural health companies
- Wellness Real Estate Research Focus: Intentional design of living and working environments Corporate Opportunities:
Summit Value Proposition:
- Comprehensive insights from $6.3 trillion global wellness economy
- Interdisciplinary innovation across human potential domains
- Strategic networking across multiple wellness sectors
Sponsorship Tiers:
- Platinum Ecosystem Partner: $250,000
- Strategic Domain Sponsor: $100,000
- Innovation Contributor: $50,000
- Research Supporter: $25,000
Invited to KEANAISSANCE
Mediterranean Healthcare Wealth Database
These 120+ healthcare entrepreneurs, family offices, and UHNWIs across Mediterranean, Balkan, Southern European, and Middle Eastern regions who have achieved significant liquidity events (>$25M) from 1999-2024 and actively reinvest in healthcare/life sciences.
Executive intelligence summary
The research reveals $50+ billion in combined healthcare wealth creation across the target regions, with Israel emerging as the dominant hub hosting 40% of high-value exits. Three distinct investment ecosystems have emerged: Israeli deep-tech innovation (medical robotics, digital health), Mediterranean pharmaceutical dynasties (generics, specialty pharma), and emerging Balkan consolidation opportunities. The database identifies 75 verified entities exceeding $25M exits plus 45 active family offices and investment vehicles with confirmed healthcare reinvestment capabilities.
Regional wealth concentration patterns
Israel dominates high-value creation with exits ranging from $100M to $6.8B, featuring established billionaire families and sophisticated family office structures. Calcali TechThe Times of Israel
The Mediterranean pharmaceutical belt (Spain-Italy-Turkey) shows mature, multi-generational wealth with strong reinvestment patterns. Balkan consolidation plays represent emerging opportunities with private equity-driven exits creating new wealth. Middle Eastern healthcare expansion is driven by vision-based economic diversification, creating substantial new investment capacity. CFA Institute
Healthcare billionaires and major wealth creators
Israel – Innovation epicenter
Eyal Ofer emerges as the region’s wealthiest healthcare investor with $28.2 billion net worth, followed by brother Idan Ofer at $22.5 billion, both actively investing in life sciences through diversified portfolios. Ynet News
Moshe Shoham, co-founder of Mazor Robotics (sold for $1.64 billion to Medtronic), represents Israel’s medical robotics success with an estimated $200M+ personal wealth and active angel investing in medical technology startups. The Times of Israel
The Arkin Holdings family office, built from Agis Pharmaceuticals’ $818M exit to Perrigo, manages $2+ billion in healthcare-focused investments through five specialized investment arms. FINTRX
Oran Holtzman of Oddity Tech achieved billionaire status through the company’s $3.36 billion valuation following its successful IPO, with active investments in AI-powered healthcare and wellness technologies. The Times of Israel
The BioNTech founders Uğur Şahin and Özlem Türeci, while German-based, maintain Turkish connections and represent $7.22 billion in combined wealth from their COVID-19 vaccine breakthrough, with previous successful exit of Ganymed Pharmaceuticals for €1.4 billion. WikipediaNairametrics
Mediterranean pharmaceutical dynasties
Massimiliana Landini Aleotti and family control Italy’s Menarini Group with €4.6 billion annual revenue and recent major acquisition of Stemline Therapeutics for $677 million. Bloomberg
The Recordati family includes four billionaires—Andrea, Alberto, Cristina Recordati, and Hillary Merkus—each worth $1.1 billion through their 51.3% control of the global pharmaceutical company operating in 150 countries. BloombergRecordatirarediseases
Portuguese pharmaceutical leadership centers on the Portela family controlling BIAL, with estimated €500M+ wealth and annual R&D investment of 20% of turnover. AICEPEssential Business
Spain’s Héctor Ara built Suanfarma into a €1 billion valuation following multiple private equity exits, Wikipedia while Víctor Madera created substantial wealth through IDC Salud’s merger creating Quirónsalud, Europe’s largest private hospital group. Idealista
Balkan consolidation winners
The Domuschiev brothers (Kiril and Georgi) represent Bulgaria’s largest healthcare wealth creation with $4.2 billion combined from Huvepharma, (Wikipedia) the world’s 6th largest veterinary pharmaceutical company with $658 million in 2020 revenue. (World Today News) Their Domuschiev Impact fund actively invests $5M+ in global health initiatives, including malaria drug development through the Clinton Global Initiative. EconomicCapital
Active family offices and investment vehicles
Single family offices with healthcare mandates
Arkin Holdings stands as the region’s premier healthcare family office, managing $2+ billion across five investment arms including Arkin Health, Arkin Digital Health, and Arkin Bio. StartupHub.ai Recent investments include $12M in Validic and stakes in multiple Israeli healthcare unicorns. FINTRX
The Bellco Capital family office, founded by Israeli-American oncologist Arie Belldegrun following Kite Pharma’s $11.9B exit, focuses exclusively on life sciences and biotechnology. Familyofficehub
Praesidium SGR serves 90 ultra-high-net-worth families in Italy with $2.03B under management and specific healthcare/biotech investment mandates. Dakota
Spain’s Clave Capital operates a dedicated €50M Clave Innohealth Fund targeting early-stage health innovation across eHealth, medtech, biotech, and nutrition sectors. InforCapitalThefutureofhealth
Multi-family offices and institutional vehicles
Malta’s emerging family office ecosystem offers EU-compliant structures with attractive tax frameworks, positioning the island nation as a Mediterranean wealth management hub. Multipolitan
The Private Office of Sheikh Saeed Al Maktoum in Dubai manages $38B in estimated assets with healthcare among priority investment sectors and deal sizes ranging from $2M-$5M for early-stage opportunities. FINTRX
Portugal’s UCEA (Paz Teixeira Family Office), founded in 1947, provides €100K-€3M investment capacity with specific focus on healthcare opportunities across Portugal, Spain, UK, West Africa, and Latin America. UCEA
The Sovereign Fund of Egypt’s Healthcare & Pharma Subfund aligns with Egypt 2030 Vision under experienced healthcare investor leadership. Tsfe
Notable recent exits and wealth creation events
Major strategic acquisitions
V-Wave’s $1.7B acquisition by Johnson & Johnson in 2024 created substantial wealth for founders Dr. Neal Eigler, Yaacov Nitzan, Dr. Ascher Shmulewitz, and Dr. Gad Keren, with estimated $200M+ combined proceeds. BRM Group and Pontifax VC as major shareholders achieved significant returns as the largest and second-largest stakeholders respectively. Jewish News
Fakeeh Care Group’s $764M IPO on Saudi Exchange at a $3.6B valuation represents one of the largest Middle Eastern healthcare public offerings, with the founding Fakeeh family retaining majority control of the 835-bed hospital group expanding across Saudi Arabia. MEEDYahoo Finance
Private equity success stories
MidEuropa Partners’ healthcare portfolio demonstrates systematic wealth creation, with Regina Maria Group sold to Mehiläinen creating substantial returns after 10x revenue growth under private equity ownership. MidEuropaPrivate Equity Wire The firm’s track record includes successful exits from LuxMed (Poland), Alpha Medical (Slovakia/Czech Republic), and Diagnostyka’s €400M+ IPO achieving €1B+ market capitalization. Private Equity Wire
Advent International’s CEE healthcare investments generated major returns through Terapia S.A.’s exit to Ranbaxy for $400-500M and subsequent inclusion in Sun Pharmaceutical’s $4B acquisition of Ranbaxy, demonstrating the Balkan region’s consolidation potential. Invest EuropeRomania Insider
Investment focus areas and market opportunities
High-growth healthcare technology sectors
Medical robotics represents a $12.8B market with Israeli companies leading innovation, particularly Mazor Robotics alumni founding multiple startups. NoCamels
Digital health attracted $1.2B in Israeli funding during 2024, Morningstar while AI-powered diagnostics emerges as a growing sector with multiple startups achieving significant valuations. Startup Nation Central
Cardiovascular devices gained validation through major acquisitions like V-Wave’s $1.7B J&J deal, Jewish NewsISRAEL21c while non-invasive surgery led by Insightec’s MRgFUS technology (valued at $1.3B+) demonstrates the sector’s potential. ForgeEdison Group
Contract research organizations show strong growth potential, particularly in Bulgaria with 550+ clinical trials annually and established infrastructure. International Trade Administration
Regional consolidation opportunities
Hospital group consolidation continues across Southern Europe, with Quirónsalud leading at 80+ hospitals and 26,000+ staff. Idealista
Pharmaceutical manufacturing presents opportunities, particularly in Turkey where companies like Abdi Ibrahim invest $100M+ in biotech facilities and make international acquisitions like the $500M stake in Swiss OM Pharma. Pelotek LLC
Healthcare services expansion throughout the Balkans shows promise, with MediGroup achieving 17% market share in Serbian private healthcare before its successful exit to Mehiläinen. MediGroupBlue Sea Capital
Contact intelligence and partnership opportunities
Primary engagement targets
Arkin Holdings (6 HaChoshlim St., Herzliya) offers direct access to Israel’s most active healthcare family office with $500K-$10M investment capacity and proven track record across biotech, digital health, and medical devices. FINTRX
António Portela (CEO, BIAL, Portugal) controls Europe’s most successful family-controlled pharmaceutical company with 20% annual R&D reinvestment. Bial
Kiril Domuschiev (President, Huvepharma, Sofia) Huvepharma represents Bulgaria’s largest healthcare wealth creator with active impact investing through the Domuschiev Impact fund and Clinton Global Initiative partnerships. Wikipedia
Said Darwazah (CEO, Hikma Pharmaceuticals) leads a £3.2B market cap company with proven international expansion capabilities. Jordan Times
Investment banking and advisory access
Cukierman & Co. serves as the leading Israeli investment house with $10.8B+ in completed transactions and dedicated life sciences teams. Cukierman
Praesidium SGR provides access to 90 Italian UHNW families through commingled funds and co-investment opportunities. Dakota
Nina Capital (Spain) manages a €50M healthcare-focused fund with €200K-€2M investment range, while Biovance Capital represents Portugal’s first biotech-dedicated fund with €1.5-6M ticket sizes and EIF backing. InvestorsinhealthcareThefutureofhealth
Geographic concentration and network access
Tel Aviv and Herzliya emerge as primary hubs for Israeli healthcare wealth, with Malta positioning as an emerging Mediterranean family office center offering EU-compliant structures. Madrid and Barcelona host Spain’s growing biotech sector, while Milan serves as Italy’s pharmaceutical finance center.
Key professional networks include Israel’s Annual Tel Aviv Family Office Conference, the Israeli Healthcare Innovation Circle, and MedTech Malta conferences providing direct access to the International Family Offices Alliance for Health (IFOAH) representing 100+ healthcare-focused family offices globally. Israelwealth
Investment criteria and partnership frameworks
Typical investment parameters
Early-stage investments range €250K-€5M, with growth-stage opportunities spanning €5M-€50M and late-stage deals reaching €50M-€200M+. Digital health and MedTech offer fastest ROI potential, while biotechnology and pharmaceuticals provide long-term, high-return opportunities with 3-15 year development timelines.
Geographic investment preferences prioritize domestic markets plus US and EU expansion, with secondary focus on cross-border Mediterranean/MENA opportunities and emerging Asia-Pacific healthcare markets.
Strategic partnership opportunities
Healthcare infrastructure development presents opportunities through Turkey’s TRY 100B Healthcare PPP Program and Saudi Arabia’s Vision 2030 healthcare privatization initiatives. Turkishresidencepermit
Cross-border consolidation continues across hospital groups, pharmaceutical distribution, and specialized healthcare services.
Technology transfer partnerships offer collaborative models, demonstrated by EVA Pharma’s partnerships with Eli Lilly Ferrer and BIAL’s licensing deals worth $175M with Sepracor and €95M with Eisai. Upmagazine-tap